Saturday, November 7, 2026

Peloton Already 5% Down, Almost Hour Before The NASDAQ Open

Peloton Already 5% Down, Almost  Hour Before The NASDAQ Open

(VIANEWS) - The NASDAQ opens in less than hour and Peloton's pre-market value is already 5.06% down.

Peloton's last close was $3.95, 67.14% below its 52-week high of $12.02.

The last session, NASDAQ finished with Peloton (PTON) rising 5.61% to $3.95. NASDAQ rose 0.32% to $16,306.64, after three consecutive sessions in a row of gains, on what was a somewhat positive trend trading session.

About Peloton

Peloton Interactive, Inc. operates interactive fitness platform in North America and internationally. The company offers connected fitness products with touchscreen that streams live and on-demand classes under the Peloton Bike, Peloton Bike+, Peloton Tread, Peloton Tread+, Peloton Guide, and Peloton Row names. The company markets and sells its interactive fitness products directly through its retail showrooms and at onepeloton.com. Peloton Interactive, Inc. was founded in 2012 and is headquartered in New York, New York.

Earnings Per Share

As for profitability, Peloton has a trailing twelve months EPS of $-2.44.

Moving Average

Peloton's value is way below its 50-day moving average of $5.18 and way below its 200-day moving average of $6.20.

Revenue Growth

Year-on-year quarterly revenue growth declined by 6.2%, now sitting on 2.73B for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Peloton's EBITDA is 1.21.

Sales Growth

Peloton's sales growth for the next quarter is 1.9%.

More news about Peloton (PTON).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com